Keyword → Vinay Prasad

FDA's Vinay Prasad to Exit Biologics Post in April, Sending Biotech Stocks Sharply Higher

Mar 9, 2026

positive

FDA's Vinay Prasad to Exit Biologics Post in April, Sending Biotech Stocks Sharply Higher

The announced departure of Dr. Vinay Prasad, director of the FDA's Center for Biologics Evaluation and Research, triggered a significant rally in biotech equities Monday, with uniQure surging more than 31% in premarket trading. Investors interpreted the news as a signal that the agency may adopt a more predictable and industry-friendly regulatory posture for vaccines, gene therapies, and rare disease treatments.

MRNAQURERGNXNTLAEDIT +20 more
FDAVinay PrasadCBERbiotech stocksgene therapyModernauniQuredrug approvals
Read full analysis →

What we cover

STKMRKT publishes daily stock market news covering earnings reports, pre-market movers, Fed policy, macroeconomic data releases, sector trends, and cryptocurrency updates. Every article is written for active traders and long-term investors who need fast, actionable context — not noise.

Market Data

Earnings

Learn

Tools

Page 1 of 1